Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes-Reference-Cited by-同舟云学术

Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes

Published:2022-03-03 Issue:6 Volume:15 Page:1449-1459
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Safadi Rifaat¹,Rahimi Robert S.²,Thabut Dominique³,Bajaj Jasmohan S.⁴,Ram Bhamidimarri Kalyan⁵,Pyrsopoulos Nikolaos⁶,Potthoff Amy⁷,Bukofzer Stan⁷,Wang Laurene⁸,Jamil Khurram⁹,Devarakonda Krishna R.¹⁰

Affiliation:

1. Director of The Liver Institute Hadassah Medical Organization Hadassah Hebrew University Medical Center, Jerusalem, Israel

2. Baylor Scott and White Hospital Baylor University Medical Center Dallas Texas USA

3. Brain Liver Pitié‐Salpêtrière (B‐LIPS) Study Group Paris Sorbonne Université, Assistance Publique–Hôpitaux de Paris Paris France

4. Department of Medicine Virginia Commonwealth University and McGuire VA Medical Center Richmond Virginia USA

5. Miller School of Medicine University of Miami Miami Florida USA

6. Rutgers New Jersey Medical School and University Hospital Newark New Jersey USA

7. Ocera Therapeutics, Inc. Redwood City California USA

8. INDAPharma, LLC Chapel Hill North Carolina USA

9. Mallinckrodt Pharmaceuticals Hampton New Jersey USA

10. Mallinckrodt Pharmaceuticals Webster Groves Missouri USA

Funder

Mallinckrodt Pharmaceuticals

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13257

Reference20 articles.

1. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

2. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options

3. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions

4. Ammonia Levels and Hepatic Encephalopathy in Patients with Known Chronic Liver Disease

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ammonia-induced stress response in liver disease progression and hepatic encephalopathy;Nature Reviews Gastroenterology & Hepatology;2024-09-09

2. Cerebral Aspects of Portal Hypertension;Clinics in Liver Disease;2024-08

3. NHH promotes Sepsis-associated Encephalopathy with the expression of AQP4 in astrocytes through the gut-brain Axis;Journal of Neuroinflammation;2024-05-27

4. Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies;Biochemical Pharmacology;2024-04

5. Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights;Frontiers of Medicine;2024-02